CORBEVAX®, A COVID19 VACCINE DEVELOPED BY BIO E-INDIA BASED ON THE RBD PROTEIN ANTIGEN TECHNOLOGY FROM TEXAS CHILDREN’S HOSPITAL CENTER FOR VACCINE DEVELOPMENT, RECEIVES WORLD HEALTH ORGANIZATION EMERGENCY USE LISTING APPROVAL

The RBD antigen of SARS-CoV-2 producing yeast strain from Texas Children’s Hospital / Baylor College of Medicine was used by Biological E Limited, India to develop & manufacture CORBEVAX®, the COVID-19 vaccine and approximately 100 million doses have been administered to people in India…